DiObex and Camurus , Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology

March 18, 2008 - DiObex and Camurus announced today that they have signed a license agreement to develop DIO-901(very low dose glucagon) in the Camurus drug delivery technology, FluidCrystal(R). The development candidate is an extended release formulation of low dose glucagon for the prevention of insulin-induced hypoglycemia in patients with diabetes."Intensive glycemic control is beneficial for patients with diabetes, but it increases their risk of hypoglycemia, which can lead to a spectrum of problems ranging from reduced quality of life to coma and death," said David Cory, DiObex CEO. "This license agreement and development program reflects our commitment to deliver an extended release form of low dose glucagon to the market for the prevention of insulin-induced hypoglycemia."... DiObex 's Press Release - Camurus ' Press Release -

DiObex, Patent for the Prevention of Insulin-Induced Hypoglycemia

January 8, 2008 - DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901 , in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon... DiObex' Press Release-